Current News

Contact | Print version | Send article | RSS feed

Debiopharm and Cambridge Antibody Technology enter into an exclusive agreement to develop and market SC-1 for gastric carcinomas

17 Oct 2006 - The Debiopharm Group and Cambridge Antibody Technology (CAT) have entered into an exclusive worldwide licensing agreement to develop and commercialise SC-1 and all derivative products generated by the use of the SC-1 Technology. SC-1, developed by Debiopharm, is a fully human monoclonal IgM antibody that targets CD55SC-1, a cell surface receptor specifically expressed on gastric carcinoma cells. Under the terms of the agreement, Debiopharm will receive upfront and milestone payments from CAT as well as royalties on potential future sales.
 
SC-1 has completed an academic Phase I/II study in 51 resectable gastric cancer patients. SC-1 has been granted orphan drug designation by the US FDA for gastric cancer.